Male Urethral Stricture
At a glance
- Assess: record obstruction/infection symptoms, previous instrumentation and repairs, radiation/trauma and lichen sclerosus; obtain flow/PVR and define location, length and lumen with urethrography and/or endoscopy before choosing repair.[1]
- Options: selected primary short non-obliterative bulbar strictures may have dilation/DVIU or urethroplasty. After recurrence, discuss urethroplasty; a drug-coated balloon is an option for selected recurrent short bulbar disease. Perineal urethrostomy or palliation may fit individual goals.[1][24]
- Reconsider the pathway: retention or infected obstruction requires prompt drainage assessment. Penile/long strictures, obliteration, LS, radiation and failed repairs require a tailored reconstructive plan; do not select treatment from scar depth alone.[1]
- Follow-up: establish postoperative symptom/flow baselines and risk-adjusted surveillance. Investigate recurrent symptoms or deteriorating flow; follow after urethroplasty for at least a year, with longer surveillance for higher-risk repairs.[23]
Compare OPEN and ROBUST III: durability, anatomy and symptom improvement are different outcomes.
Urethral stricture disease is one of the oldest documented conditions in urology — present in Egyptian papyri, treated by Sushruta, and still affecting millions of men worldwide. It is defined as any pathological narrowing of the anterior urethra caused by scar tissue formation within the urethral epithelium and surrounding corpus spongiosum.[1] Despite its antiquity, management has undergone fundamental transformation over the past three decades, driven by a shift from repeated endoscopic palliation toward durable reconstructive repair.
For procedural selection and the full range of repairs, see the Urethral Reconstruction treatment atlas.
Epidemiology
The estimated prevalence of urethral stricture in developed countries is approximately 0.9%, though this likely underestimates the true burden of disease given underdiagnosis.[2] Population-level data suggest a prevalence of 1–9 per 1,000 men, with incidence rising steeply with age — men over 85 face a 12-fold higher risk than younger cohorts.[1]
Age distribution varies by cause and referral population; iatrogenic disease becomes particularly relevant with age. Older age does not exclude stricture disease.[4]
Anatomic Distribution
Approximately 80–92% of strictures involve the anterior urethra.[5][3]
| Location | Proportion of All Strictures |
|---|---|
| Bulbar urethra | 40–47% (most common) |
| Penile urethra | ~30% |
| Multifocal / panurethral | 10–15% |
| Posterior urethra | 8–20% |
The bulbar urethra's predominance reflects its susceptibility to perineal trauma, instrumentation, and the unique vascularity of the bulbospongiosus region. Posterior strictures — membranous and prostatic — are almost exclusively iatrogenic or traumatic.[4]
Etiology
The etiology of urethral stricture disease has shifted dramatically in the modern era. In developed countries, iatrogenic causes now predominate; in low-income countries, trauma remains the leading cause due to road traffic injuries and limited healthcare infrastructure.[1]
Etiology Overview
| Category | Proportion | Key Causes |
|---|---|---|
| Iatrogenic | 38–52% | Urethral catheterization (16–60% of iatrogenic), TURP (9–40%), hypospadias repair (12–16%), prostatectomy (21–25% in men >45 yr) |
| Idiopathic | 20–36% | Unknown; once attributed to subclinical repeated perineal trauma (SRPT), now challenged |
| Inflammatory | 14–16% | STIs (gonorrhea historically dominant), predominantly penile urethra (48%) |
| Lichen sclerosus (LS) | 13–14% | Mean stricture length 7.45 cm; penile predominance; possible urethral cancer association |
| Traumatic | 11–22% | Pelvic fracture = 63% of trauma strictures; posterior urethra predominates |
Idiopathic Strictures: Rethinking "Microtrauma". Historically, idiopathic strictures were attributed to subclinical and repeated perineal trauma (SRPT). However, deep phenotyping studies have demonstrated that patients with idiopathic strictures have SRPT exposure rates similar to those with known etiologies — challenging this conventional wisdom. Shared inflammatory biomarker profiles between idiopathic and lichen sclerosus strictures suggest a systemic inflammatory predisposition may underlie many "idiopathic" cases.[7]
Etiology by Age and Location
Etiology varies significantly by patient age and stricture location:[6][5]
| Population | Predominant Etiologies |
|---|---|
| Age <45 years | Idiopathic, hypospadias surgery, pelvic fracture trauma |
| Age ≥45 years | Iatrogenic (68% in those over 60): TURP, prostatectomy |
| Penile strictures | Hypospadias repair, idiopathic, urethral catheterization, lichen sclerosus |
| Bulbar strictures | Idiopathic, TURP |
| Membranous/prostatic | Iatrogenic (post-prostatectomy), pelvic fracture |
| Multifocal/panurethral | Urethral catheterization |
Pathophysiology
Tissue-Level Mechanism
Urethral stricture formation results from fibrosis and scar tissue development in response to injury — whether traumatic, inflammatory, or ischemic.[8] The pathophysiologic cascade:
- Epithelial injury → bleeding, extravasation of urine into the corpus spongiosum
- Inflammatory cell infiltration → myofibroblasts and multinucleated giant cells
- Altered collagen composition → the classic human biochemical study found a higher proportion of type I and lower proportion of type III collagen in stricture scar than normal spongiosum, consistent with reduced compliance; total collagen content did not differ significantly.[26]
- Progressive spongiofibrosis → the scar encases and compresses the urethral lumen
Spongiofibrosis contributes to stricture complexity. Treatment selection also depends on length, site, lumen/obliteration, cause, previous treatment and patient goals; depth alone is not a validated selection rule.[1]
Transverse cross-section of the anterior urethra. Normal: an open, epithelium-lined lumen sits within the vascular corpus spongiosum. Stricture: spongiofibrosis — scar replacing the spongy erectile tissue — forms a rigid ring that encases and compresses the lumen to a pinhole. Fibrosis depth is one feature of disease; this schematic cannot select a repair. Location, length, etiology, obliteration and prior treatment must also be considered. (Original WARWIKI schematic)
Histopathology
Recent detailed histopathologic studies have clarified stricture biology:[9]
- Chronic inflammation is present in 44% of stricture specimens, with lymphocytes as the predominant cell type (86% of inflammatory cases) and plasma cells in 12%
- Inflammation severity: minimal 20%, mild 39%, moderate 39%, severe 2%
- Inflammation patterns differ by etiology: mild-to-severe inflammation in 27% of trauma strictures, 54% of idiopathic, and 48% of LS strictures (P = 0.036)
- Isolated bulbomembranous strictures show largely absent inflammation (only 9%), suggesting direct mechanical injury rather than an inflammatory mechanism
- Fibrosis does not significantly differ between etiologies, supporting a common final pathway of scar formation regardless of initiating insult[7]
Molecular Biomarkers
Deep phenotyping has identified systemic inflammatory and fibrotic biomarkers elevated in stricture patients versus controls:[7]
- Interleukin-9 (IL-9) — elevated in inflamed strictures; correlates with inflammation severity (Spearman's ρ 0.224, P = 0.014)
- Platelet-derived growth factor-BB (PDGF-BB)
- CCL5
These cytokines are implicated in fibrotic conditions in other organ systems and may represent future therapeutic targets for scar prevention or modulation.
Clinical Presentation
Symptoms
Men most commonly present with obstructive voiding symptoms (LUTS), reported by over 90% of patients:[1][8]
- Weak or reduced urinary stream
- Incomplete bladder emptying
- Urinary hesitancy and straining to void
- Intermittent or split stream
- Post-void dribbling
- Spraying of urine
Irritative symptoms may also occur: dysuria, urinary frequency, urgency, and nocturia.
Additional presentations include:
- Acute urinary retention (AUR) — present in 32.6% of patients at diagnosis[10]
- Recurrent urinary tract infections (particularly with elevated post-void residuals)
- Rising post-void residual volumes
- Hematuria
- Urinary incontinence (overflow or post-void dribbling)
- Ejaculatory dysfunction (minority of patients)
- Rare: urethral carcinoma, Fournier's gangrene, bladder atonia[8]
Physical Examination
- Palpable urethral thickening or induration — correlates with severity of spongiofibrosis
- White plaques or patches on the glans/prepuce — characteristic of lichen sclerosus
- Palpably distended bladder — chronic urinary retention
- Perineal/scrotal fluctuance — urethral abscess or extravasation (urgent)
Complications and Natural History
Urethral stricture is frequently a morbid condition: 40.6% of patients experience at least one stricture-related complication.[10]
| Complication | Incidence |
|---|---|
| Acute urinary retention | 32.6% |
| Difficult catheterization requiring emergent intervention | 16.0% |
| Urethral abscess or urosepsis | 5.0% |
| Renal failure | 3.1% |
| Life-threatening complication (any) | 7.0% |
Risk factors for complications (multivariate analysis):[10]
- Longer stricture length (OR 1.1 per cm)
- Absence of preceding LUTS (OR 3.8) — strictures presenting acutely without warning
- Posterior stenosis (OR 3.0)
- Trauma etiology (OR 1.6)
If untreated, strictures cause progressive obstructive uropathy with potential renal impairment. The severity of disease at presentation is substantial — 83% of strictures cause obstruction of more than two-thirds of the urethral lumen.[4]
Female Urethral Stricture
Female urethral strictures are most commonly iatrogenic, often following traumatic catheterization or multiple dilations that cause fibrotic healing from bleeding and extravasation.[1] Other causes include blunt pelvic trauma, obstetric complications (cephalopelvic disproportion), malignancy, radiation, urethrovaginal atrophy, recurrent infections, and skin diseases (lichen planus, lichen sclerosus).
Diagnosis is challenging due to non-specific presentation and unclear diagnostic criteria. Patients present with LUTS, recurrent UTIs, hesitancy, poor flow, frequency, urgency, urethral pain, elevated PVR, or AUR. Inability to pass even a small catheter due to distal stenosis is strongly suggestive.
Diagnosis & Workup
Diagnosis requires endoscopic or radiographic confirmation in the setting of clinical suspicion.[1] Stricture length and location are critical for treatment planning.
Imaging
| Modality | Role | Key Points |
|---|---|---|
| Retrograde Urethrography (RUG) | Gold standard for anterior urethra | Identifies location, length, severity; performed with fluoroscopy |
| Voiding Cystourethrography (VCUG) | Posterior urethra; functional significance | Combined RUG+VCUG for complete urethral mapping |
| Sonourethrography (SUG) | Spongiofibrosis assessment | Superior to RUG for measuring true stricture length and depth of fibrosis in bulbar urethra; emerging role |
| MRI | Complex posterior injuries | Best for pelvic fracture urethral injuries (PFUI) — defines distraction defect length and anatomy |
Diagnostic Procedures
Uroflowmetry: A characteristic "flat-topped" or plateau-shaped tracing with peak flow (Qmax) <10–12 mL/s is highly suggestive of stricture disease.
Urethrocystoscopy: Provides direct visualization of the urethral lumen. Key endoscopic findings:
- Epithelial pallor
- Reduced tissue elasticity
- Inability to advance the scope (tight strictures)
- Scarring pattern and distribution
Urodynamics: Generally not routinely indicated unless coexisting bladder dysfunction (e.g., neurogenic bladder, OAB, DUA) is suspected.
Classification & Grading
EAU Lumen-Based Grading System
| Category | Description | Lumen Caliber |
|---|---|---|
| 1 | Subclinical | >16 Fr |
| 2 | Low grade | 11–15 Fr |
| 3 | High grade | 4–10 Fr |
| 4 | Nearly obliterative | 1–3 Fr |
| 5 | Obliterative | 0 Fr |
Devine Classification (Spongiofibrosis Depth)
Grades strictures by depth of fibrosis from mucosal-only involvement to full-thickness fibrosis extending outside the corpus spongiosum. This descriptive scheme is not a stand-alone validated algorithm for choosing endoscopy versus urethroplasty.
LSE Classification System
Developed by Erickson et al. (2020) and validated through the Trauma and Urologic Reconstructive Network of Surgeons (TURNS) prospective database, LSE stands for Length (L), Segment (S), and Etiology (E) — not "severity."[17] The system uses retrograde urethrogram, physical exam, and patient history:
| Element | Categories |
|---|---|
| L — Length | L1 (short) / L2 (intermediate) / L3 (long) |
| S — Segment / location | S1 bulbar / S2 penile / S3 contiguous or multi-segment amenable to a single surgical approach |
| E — Etiology | E1–E6 (idiopathic, iatrogenic, trauma, lichen sclerosus, hypospadias, etc.) |
Interrater reliability 0.79 overall (L 0.76, S 0.70, E 0.93). Segment is strongly associated with both urethroplasty type (p = 0.0005) and stricture etiology (p = 0.0005).[17] The derived numeric LSE score correlates with surgical complexity and recurrence.[18]
LSE Staging System (Erickson 2025)
A subsequent formal staging system built on the LSE classification, validated with TURNS longitudinal outcomes data. Five stages with 10 substages, ranked by a Urethroplasty Triad Score (functional outcome + meatus location + number of surgeries):[19]
| Stage | Description |
|---|---|
| I | Short bulbar |
| II | Long bulbar |
| III | Penile / fossa navicularis with favorable etiology |
| IV | Penile / fossa navicularis with adverse pathology |
| V | Panurethral (three segments) |
These stages describe case mix and prognosis; they do not mandate a particular operation. LS and failed hypospadias repair require tissue-specific assessment, and some complex strictures remain suitable for a single-stage reconstruction.[1][19]
The LSE staging system is superior to both the LSE score and the U-score in predicting need for multiple stages or a nonorthotopic meatus.[19] Its key innovation is separating penile strictures by etiology (Stage III vs IV) — favorable-etiology penile strictures often manageable in one stage, while LS and hypospadias should prompt serious consideration of staged repair or perineal urethrostomy.
Comparison with Other Anterior-Stricture Classification Systems
A 2021 systematic review by John & Kahokehr identified five anterior-stricture classification systems with varying validation depth:[20]
| System | Basis | Components | Validation |
|---|---|---|---|
| U-Score (Urethral Stricture Score) | RUG + history | Length (1–3) + number (1–2) + location (1–2) + etiology (1–2); total 4–9 | Multiple external validations; predicts surgical complexity, OR time, recurrence[21][22] |
| LSE | RUG + exam + history | L (1–3), S (1–3), E (1–6) | TURNS validated; interrater reliability 0.79; predicts complexity and recurrence[17][18] |
| ULTRA Score | Sonourethrogram | Ultrasound stricture characteristics | Limited |
| Cystoscopy-based | Endoscopy | Endoscopic appearance | Limited |
| Gombe Urethrographic Score | RUG | Urethrographic features | Limited |
Head-to-head — LSE vs U-score (Kurtzman 2022, n = 187): both correlate with surgical complexity; the two scores are strongly linearly correlated.[18] The U-score has more external validation; LSE is the only system that elevates etiology to a separate classification axis — clinically the most decision-changing variable given the LS and hypospadias prognostic penalty.
Management
Indications for Intervention. Intervention is indicated for any of the following:
- Symptomatic LUTS attributable to stricture
- Acute urinary retention
- Recurrent urinary tract infections
- Bladder calculi
- Rising post-void residual threatening upper tract function
- Subclinical strictures in patients undergoing transurethral procedures (to facilitate access)
Key Contraindications.
- Avoid DVIU as definitive treatment for penile or long (>2 cm) strictures; durable success is poor, but no universal 100% recurrence rate applies.[1]
- Genital skin grafts and flaps are strictly contraindicated in patients with lichen sclerosus — LS will recur in genital skin used for reconstruction
- Hair-bearing skin must never be used for urethral substitution — causes calculi, infection, and obstruction
- Tubularized grafts without an adequate vascular bed have high restenosis rates and should be avoided
Observation
Asymptomatic, subclinical strictures (EAU Category 1, >16 Fr) may be managed with active surveillance. Intervention is deferred until symptoms develop or lumen narrows to a clinically relevant degree.
Endoscopic Management: Dilation and DVIU
Direct Visual Internal Urethrotomy (DVIU) and urethral dilation are the most commonly performed procedures for stricture disease. Either may be offered for selected primary, single, short (<2 cm), non-obliterative bulbar strictures. This is a choice between endoscopic approaches, not a claim that every short stricture is suitable or that endoscopy matches urethroplasty durability.[1]
Key limitations:
- Repeated standard endoscopic treatment has poor durability; discuss urethroplasty after recurrence rather than serial procedures with curative intent.[1][11]
- Longer strictures are poor candidates for standard dilation/DVIU; published outcomes depend on case selection and the failure definition.[1]
- Penile strictures are unlikely to respond to dilation or urethrotomy
- Repeated DVIU promotes progressive spongiofibrosis, making subsequent urethroplasty more complex
Urethroplasty may be offered as primary treatment even for short bulbar strictures when the patient prefers definitive repair, understands the trade-off of higher short-term morbidity for superior durability.[1]
Drug-Coated Balloons
Optilume’s FDA indication covers adult men with symptomatic anterior strictures ≤3 cm. Guideline selection is narrower: EAU 2026 recommends DCB for recurrent bulbar strictures <3 cm after at least two endoscopic treatments when urethroplasty is unsuitable or declined. ROBUST III compared DCB with standard endoscopy, not urethroplasty.[24][27][28]
The label requires abstinence or condom use for 30 days, plus highly effective contraception and avoiding fathering a child for at least six months when the partner could become pregnant. Treat active UTI first; paclitaxel hypersensitivity and urologic implants such as an AUS or penile implant are contraindications. Repeated treatment of the same stricture is insufficiently studied.[27] See the DCB technique and counseling page.
Intralesional adjuncts such as mitomycin C are a different intervention. EAU advises their use only within clinical trials because regimens and long-term safety are uncertain.[28]
Urethroplasty
Urethroplasty is the definitive treatment for urethral stricture disease. It is recommended upfront for long bulbar strictures, penile strictures, and recurrent strictures after failed endoscopic management.
By Stricture Location and Length
| Stricture pattern | Treatment discussion | Evidence boundary |
|---|---|---|
| Primary, single, short non-obliterative bulbar | Dilation/DVIU or urethroplasty after counselling | Options are not equivalent in long-term durability |
| Long bulbar | Usually graft augmentation/substitution; tailor to scar and viable plate | A single success percentage does not apply to all repairs |
| Penile / LS-associated | Tailored single-stage or staged reconstruction; avoid genital skin in LS | Etiology, tissue quality and prior repair matter |
| Recurrent after standard endoscopy | Urethroplasty; selected short bulbar cases may consider drug-coated balloon | OPEN favoured urethroplasty for reintervention; ROBUST III did not compare with urethroplasty |
| Panurethral / complex | Specialist reconstruction or perineal urethrostomy according to goals | Discuss morbidity and the possibility of staged treatment |
Excision and Primary Anastomosis (EPA)
Anastomotic repair is an option for selected short bulbar strictures when a tension-free repair is feasible. Transecting EPA is particularly relevant to short traumatic obliteration; non-transecting or graft-based approaches may reduce penile complications in other short bulbar strictures. Prior TURP alone is not an indication to transect the urethra.[1]
In the Scandinavian randomized trial of 151 men with short bulbar strictures, transecting EPA caused more reported penile complications, particularly shortening and reduced glans filling, than BMG. Postoperative IIEF-5 scores did not differ; penile complications and erectile dysfunction are not interchangeable endpoints.[25]
Substitution (Graft/Flap) Urethroplasty
Indicated for longer strictures, multiple prior repairs, compromised local tissue, and penile involvement.
Oral mucosa is the first-choice graft material:[1]
- Buccal mucosal graft (BMG) and lingual mucosal graft (LMG) are alternatives; pooled success did not differ significantly (RR 1.03, 95% CI 0.96–1.10), which does not prove equivalence or identical donor-site morbidity[1]
- Lingual mucosa is thinner and may offer advantages for distal urethral and meatal reconstruction[1][14]
- Buccal mucosa properties: thick epithelium resistant to wet environment, thin vascularized lamina propria, accessible harvest, minimal donor morbidity
Technique selection by stricture characteristics:[14]
| Technique | Indication |
|---|---|
| Ventral or dorsal onlay BMG | Bulbar strictures (comparable success either approach) |
| Barbagli dorsal onlay | Bulbar; graft quilted to tunica albuginea — gold standard |
| Two-sided dorsal + ventral onlay (Palminteri) | Obliterative bulbar segments |
| Augmented anastomotic urethroplasty | Combining excision with onlay for moderate-length bulbar strictures |
| Asopa technique (dorsal inlay via ventral sagittal urethrotomy) | Penile strictures |
| Kulkarni technique (dorsolateral onlay, one-sided dissection) | Penile and panurethral strictures |
| Penile fasciocutaneous flap (Orandi) | Penile strictures — especially without LS |
For complex multi-segment strictures (>10 cm spanning penile and bulbar urethra), reconstruction uses one-stage or multi-stage techniques with OMG, penile fasciocutaneous flaps, or combinations. These cases should be performed at high-volume reconstructive centers.[1]
The OPEN Trial. The landmark OPEN trial (Goulao et al., Eur Urol 2020) randomized men with recurrent bulbar urethral stricture to open urethroplasty versus endoscopic urethrotomy. While both treatments improved voiding symptoms similarly at 24 months, urethroplasty resulted in significantly fewer reinterventions (hazard ratio 0.52, 95% CI 0.31–0.89).[11][12] Its durability finding applies to recurrent bulbar disease; superiority was not shown for the primary symptom endpoint.
Alternative Management
Perineal urethrostomy — a permanent perineal stoma — may be offered as a definitive alternative to urethroplasty for patients with complex strictures, multiple failed repairs, significant medical comorbidities precluding long surgery, or patient preference. The stoma provides a new outlet, but can develop stenosis and requires follow-up; revision may be needed over time.[1]
Suprapubic cystostomy for "urethral rest" may be placed prior to definitive urethroplasty in patients who are catheter-dependent or on intermittent self-dilation, allowing urethral inflammation to resolve before reconstruction.[1]
Outcomes & Efficacy
Compare like-for-like outcomes: anatomic patency, absence of reintervention, symptom improvement and sexual function answer different questions. Generic percentages from different series should not be ranked as though patients, techniques and follow-up were identical. OPEN demonstrated fewer reinterventions with urethroplasty in recurrent bulbar disease without superiority on its primary symptom endpoint; ROBUST III demonstrated better short-term anatomy than standard endoscopy in a selected recurrent population.[11][24]
Use the study comparison and linked technique pages for the relevant population and follow-up interval.
Complications
Minor (common): UTI, perineal pain, hematuria, dysuria, temporary urinary retention.
Major (uncommon but serious):
- Sexual/penile complications — counsel about erectile symptoms, shortening, glans filling and ejaculation separately; no technique guarantees preservation[25]
- Fournier's gangrene — rare; from urinary extravasation in neglected or infected strictures
- Renal failure — from chronic obstructive uropathy
- Malignant degeneration — rare squamous cell carcinoma arising in long-standing inflammatory strictures (particularly LS-associated)
- Urethrocutaneous fistula — possible after urethroplasty; assess drainage, infection and distal obstruction. Persistent fistula may require repair; spontaneous closure should not be assumed.
Follow-Up
After urethroplasty, EAU 2026 recommends at least one year of follow-up (strong), flexible cystoscopy at three months (weak), and subsequent surveillance adjusted to recurrence risk (weak). This updates a symptom/flow-only early surveillance approach. Uroflowmetry, post-void residual and patient-reported urinary and sexual outcomes complement anatomic assessment; worsening symptoms or flow warrant reassessment.[23]
Record anatomic patency, freedom from further intervention, and the patient's functional outcome separately. A small-caliber recurrence at three-month cystoscopy predicts later intervention risk, but an anatomic recurrence is not automatically an indication for immediate retreatment. Continue longer surveillance when the repair, tissue quality or clinical course warrants it.[23]
Practice Patterns and Guideline Adherence
Despite clear guideline recommendations, significant practice variation persists globally. A 2026 survey of Turkish urologists found that only 7% chose urethroplasty for primary 1–2 cm bulbar strictures, while 72% preferred DVIU with dilation, and 76.5% performed DVIU ≥4 times for recurrent cases — in direct conflict with guideline recommendations against repeated endoscopic management.[16]
In contrast, following publication of the 2016 AUA Guidelines, population-based data show a 0.62% annual increase in urethroplasty after failed endoscopic treatment, suggesting gradual adoption of evidence-based practice.[13]
European reconstructive urology experts demonstrate high procedural volume: 91.8% perform urethroplasty with grafts as their most frequent treatment, with 55.3% performing >20 urethroplasties annually.[15] Academic urologists demonstrate better guideline adherence than non-academic peers.[16]
Selected evidence
OPEN · 2020[11]; ROBUST III · 1 year[24]. The comparison below preserves the study-specific population, denominator, endpoint and uncertainty.
Selected studies, not a systematic review. Outcomes and populations differ; percentages across studies should not be ranked as if they were directly comparable. These source checks do not record a clinician review of the full article.
| Study and population | Comparison and results | Use and limitations |
|---|---|---|
| OPEN · 2020 Men with recurrent bulbar stricture after at least one prior intervention. Randomized n=222 | Urethroplasty vs urethrotomy Repeated patient-reported voiding symptom score · Over 24 months Symptoms improved in both groups. Mean difference −0.36; 95% CI −1.74 to 1.02; no superiority on the primary symptom endpoint. Reintervention · 24 months 15 men after urethroplasty vs 29 after urethrotomy. Hazard ratio 0.52; 95% CI 0.31–0.89. | Urethroplasty offers a durability advantage despite similar short-term symptom improvement.
|
| ROBUST III · 1 year Adult men with recurrent anterior stricture ≤3 cm and ≤12 Fr after ≥2 endoscopic treatments; IPSS ≥11 and Qmax <15 mL/s. Randomized n=127 | Paclitaxel-coated balloon vs dilation/direct-vision internal urethrotomy Anatomic success: passage of ≥14 Fr instrument · 6 months 75% vs 27%. P<.001; confidence interval not reported in inspected abstract. | An option for selected recurrent short bulbar disease; do not infer equivalence to urethroplasty.
|
See Also
- Urethral Reconstruction treatment atlas
- Male Urethroplasty
- Excision and Primary Anastomosis (EPA)
- Direct Visual Internal Urethrotomy (DVIU)
- Drug-Coated Balloon
- Blandy Perineal Urethrostomy
References
1. Wessells H, Morey A, Souter L, Rahimi L, Vanni A. "Urethral Stricture Disease Guideline Amendment." J Urol. 2023;210(1):64–71. doi:10.1097/JU.0000000000003482
2. Tritschler S, Roosen A, Füllhase C, Stief CG, Rübben H. "Urethral Stricture: Etiology, Investigation and Treatments." Dtsch Arztebl Int. 2013;110(13):220–226. doi:10.3238/arztebl.2013.0220
3. Palminteri E, Berdondini E, Verze P, et al. "Contemporary Urethral Stricture Characteristics in the Developed World." Urology. 2013;81(1):191–196. doi:10.1016/j.urology.2012.08.062
4. de Farias RB, Neto FTL, de Aguiar Cavalcanti G, Martins FE, Lima SVC. "Evaluation of the Etiological Profile, Age and Findings in Retrograde and Voiding Urethrocystography of Men With Urethral Stricture." Sci Rep. 2025;15(1):5935. doi:10.1038/s41598-025-89389-z
5. Astolfi RH, Lebani BR, Krebs RK, et al. "Specific Characteristics of Urethral Strictures in a Developing Country (Brazil)." World J Urol. 2019;37(4):661–666. doi:10.1007/s00345-019-02696-9
6. Lumen N, Hoebeke P, Willemsen P, et al. "Etiology of Urethral Stricture Disease in the 21st Century." J Urol. 2009;182(3):983–987. doi:10.1016/j.juro.2009.05.023
7. Gutierrez WR, Luo Y, Dahmoush L, et al. "Deep Phenotyping the Anterior Urethral Stricture: Characterizing the Relationship Between Inflammation, Fibrosis, Patient History, and Disease Pathophysiology." J Urol. 2024;212(1):153–164. doi:10.1097/JU.0000000000003962
8. Wong SS, Aboumarzouk OM, Narahari R, O'Riordan A, Pickard R. "Simple Urethral Dilatation, Endoscopic Urethrotomy, and Urethroplasty for Urethral Stricture Disease in Adult Men." Cochrane Database Syst Rev. 2012;12:CD006934. doi:10.1002/14651858.CD006934.pub3
9. Grimes MD, Tesdahl BA, Schubbe M, et al. "Histopathology of Anterior Urethral Strictures: Toward a Better Understanding of Stricture Pathophysiology." J Urol. 2019;202(4):748–756. doi:10.1097/JU.0000000000000340
10. King C, Rourke KF. "Urethral Stricture Is Frequently a Morbid Condition: Incidence and Factors Associated With Complications Related to Urethral Stricture." Urology. 2019;132:189–194. doi:10.1016/j.urology.2019.07.013
11. Goulao B, Carnell S, Shen J, et al. "Surgical Treatment for Recurrent Bulbar Urethral Stricture: A Randomised Open-Label Superiority Trial of Open Urethroplasty Versus Endoscopic Urethrotomy (The OPEN Trial)." Eur Urol. 2020;78(4):572–580. doi:10.1016/j.eururo.2020.06.003
12. Pickard R, Goulao B, Carnell S, et al. "Open Urethroplasty Versus Endoscopic Urethrotomy for Recurrent Urethral Stricture in Men: The OPEN RCT." Health Technol Assess. 2020;24(61):1–110. doi:10.3310/hta24610
13. Cabral JD, Alkassis M, Khalafalla K, et al. "Contemporary Trends in the Management of Urethral Stricture Disease in the Era of the AUA Guidelines." Urology. 2025. doi:10.1016/j.urology.2025.07.054
14. Horiguchi A. "Substitution Urethroplasty Using Oral Mucosa Graft for Male Anterior Urethral Stricture Disease: Current Topics and Reviews." Int J Urol. 2017;24(7):493–503. doi:10.1111/iju.13356
15. Campos-Juanatey F, Fes-Ascanio E, Adamowicz J, et al. "Contemporary Management of Male Anterior Urethral Strictures by Reconstructive Urology Experts — Results From an International Survey Among ESGURS Members." J Clin Med. 2022;11(9):2353. doi:10.3390/jcm11092353
16. Kaçtan Ç, Abali T, Vosoughi O, et al. "Management of Urethral Stricture: Translating Guidelines Into Clinical Practice." World J Urol. 2026;44(1):212. doi:10.1007/s00345-026-06312-5
17. Erickson BA, Flynn KJ, Hahn AE, et al. Development and validation of a male anterior urethral stricture classification system. Urology. 2020;143:241-247. doi:10.1016/j.urology.2020.03.072
18. Kurtzman JT, Kosber R, Kerr P, Brandes SB. Evaluating tools for characterizing anterior urethral stricture disease: a comparison of the LSE system and the urethral stricture score. J Urol. 2022;208(5):1083-1089. doi:10.1097/JU.0000000000002880
19. Erickson BA, Tuong MN, Zorn AN, et al. Development and validation of the Length, Segment, and Etiology anterior urethral stricture disease staging system using longitudinal urethroplasty outcomes data from the Trauma and Urologic Reconstructive Network of Surgeons. J Urol. 2025;213(4):512-523. doi:10.1097/JU.0000000000004369
20. John A, Kahokehr AA. Classification systems for anterior urethral stricture disease in men: a systematic review. World J Urol. 2021;39(3):761-769. doi:10.1007/s00345-020-03250-8
21. Eswara JR, Han J, Raup VT, et al. Refinement and validation of the urethral stricture score in categorizing anterior urethral stricture complexity. Urology. 2015;85(2):474-7. doi:10.1016/j.urology.2014.10.011
22. Alwaal A, Sanford TH, Harris CR, et al. Urethral stricture score is associated with anterior urethroplasty complexity and outcome. J Urol. 2016;195(6):1817-21. doi:10.1016/j.juro.2015.12.100
23. European Association of Urology. EAU Guidelines on Urethral Strictures. 2026, sections 11.1 and 11.6. Official full guideline.
24. Elliott SP et al. One-Year Results for the ROBUST III Randomized Controlled Trial Evaluating the Optilume Drug-Coated Balloon for Anterior Urethral Strictures. 2022. doi:10.1097/JU.0000000000002346.
25. Nilsen OJ, Holm HV, Ekerhult TO, et al. "To Transect or Not Transect: Results from the Scandinavian Urethroplasty Study, a Multicentre Randomised Study of Bulbar Urethroplasty Comparing Excision and Primary Anastomosis Versus Buccal Mucosal Grafting." Eur Urol. 2022;81(4):375–382. doi:10.1016/j.eururo.2021.12.017.
26. Baskin LS, Constantinescu SC, Howard PS, et al. Biochemical characterization and quantitation of the collagenous components of urethral stricture tissue. J Urol. 1993;150(2 Pt 2):642–647. doi:10.1016/S0022-5347(17)35572-6.
27. FDA. Optilume Urethral Drug Coated Balloon: Instructions for Use, P210020. Indications, contraindications, warnings and precautions. Approved labeling.
28. European Association of Urology. Urethral Strictures: Disease Management in Males. 2026. Drug-coated balloon dilatation and intralesional injections. Guideline.